Translating Mechanistic Understanding of First-in-Class Molecular Glue Degraders to Guide Clinical Trial Design & Enable Safe Entry Into the Clinic

• Defining PK/PD and mechanistic drivers of a first-in-class molecular glue degrader to inform dose selection, therapeutic window expectations and early safety strategy
• Integrating modelling, biomarker planning and preclinical pharmacology to justify indication prioritisation and guide a robust first-in-human study design
• Building a scalable development framework that enables pipeline expansion into non-oncology indications while maintaining selectivity, safety and chronic-use suitability

Speakers:

Xiaobing Qian

CDO

Degron Therapeutics